OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zain on Targets Under Investigation in T-Cell Lymphomas

November 6th 2019

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.

Dr. Mailankody on CASSIOPEIA Results in Newly Diagnosed Multiple Myeloma

November 6th 2019

Sham Mailankody, MBBS, discusses results of the CASSIOPEIA trial in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLC

November 6th 2019

Khaled A. Hassan, MD, MS, discusses the results of the FLAURA trial, which compared osimertinib with first-generation TKIs in patients with EGFR-mutant metastatic non–small cell lung cancer.

Dr. Wozniak on Sequencing Immunotherapy in Lung Cancer

November 5th 2019

Antoinette Wozniak, MD, FACP, FASCO, discusses sequencing with immunotherapy and chemoradiation in select patients with stage III lung cancer.

Dr. Lawrenz on Hypofractionated Radiotherapy in Soft Tissue Sarcoma

November 5th 2019

Joshua M. Lawrenz, MD, discusses a study looking at hypofractionated radiotherapy in soft tissue sarcoma.

Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer

November 5th 2019

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

November 5th 2019

Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Dr. Long on Including Patients With Melanoma Who Have Brain Mets on Clinical Trials

November 5th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses how to efficiently enroll patients with melanoma who have brain metastases in clinical trials.

Dr. Vidal on Increasing Access to HER2-Targeted Therapy With Biosimilars

November 4th 2019

Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.

Dr. Ho on Frontline Treatment Regimens in mRCC

November 4th 2019

Thai H. Ho, MD, PhD, discusses frontline treatment regimens in metastatic renal cell carcinoma.

Dr. Meric-Bernstam on the Safety and Efficacy of ZW25 in HER2-Expressing Solid Tumors

November 4th 2019

Funda Meric-Bernstam, MD, discusses the safety and efficacy of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumors.

Dr. Kerrigan on Sequencing Challenges in ALK+ NSCLC

November 4th 2019

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Giralt on Transplant Eligibility Criteria in Multiple Myeloma

November 2nd 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCL

November 2nd 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

Dr. Smith on PI3K Inhibitors in CLL

November 2nd 2019

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Kaubisch on Treatment Options for HCC

November 2nd 2019

Andreas Kaubisch, MD, discusses available treatment options for hepatocellular carcinoma.

Dr. Sonpavde on the Safety Profile of Erdafitinib in Bladder Cancer

November 2nd 2019

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Dr. Park on Updates With CAR T Cells in ALL

November 1st 2019

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Mato on Rituximab Biosimilars in CLL

November 1st 2019

Anthony R. Mato, MD, MSCE, discusses the introduction of rituximab biosimilars in chronic lymphocytic leukemia.

Dr. Benson on Frontline Treatment Considerations in mCRC

November 1st 2019

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.